Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Groupon

Spotify

Booking Hlds

Citigroup

CyberArk Software

GrubHub

Morgan Stanley

Match Group

PepsiCo

Peloton

Over halfway through the trading day on Monday, and the broad markets have retreated.

Citigroup, Gilead, Groupon, Morgan Stanley, Spotify and More Tuesday Afternoon Analyst Calls

H&R Block

Kraft Heinz

Lumen Technologies

Altria

With markets at record highs and interest rates at record lows, consider these five dividend stocks to buy for value and yield. The post 5 Undervalued Dividend Stocks to Buy appeared first on InvestorPlace.

5 Undervalued Dividend Stocks to Buy

Biogen

Deluxe

If you want to increase your likelihood of finding stocks that could beat the market, one method is to choose stocks that rank highly on the "Magic Formula" criteria.

3 Magic Formula Stock Picks for the Value Investor

In trading on Monday, shares of Gilead Sciences entered into oversold territory, hitting an RSI reading of 29.95

Oversold Conditions For Gilead Sciences

Gilead Sciences spent 2020 acquiring companies, in a difficult year, when a lot didn't go the company's way. The company has an impressive portfolio of assets. It has a near 5% dividend. The year 2021 has numerous Oncology milestones.

After Gilead Science's Year Of Acquisitions, 2021 Is When It Becomes An Oncology Powerhouse

The stock price of Gilead Sciences, Inc. (NASDAQ: GILD) has seen a target price decrease from $75 to $72 by Citi. These are the details.

Gilead Stock Price: $72 Target By Citi

This blue-chip biotech is a risky bet going forward, but it is also dirt cheap.

Where Will Gilead Sciences Be in 1 Year?

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Daniel O'Day, Gilead's Chairman and Chief Executive Officer, will provide an overview of the company at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11 at 12:40 p.m. Pacific Time. The live webcast can be accessed at the company's Investors page at http://investors.gilead.com. Please connect to the company's website at least 15 minutes prior to the start of the presentation to

Gilead Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021

Regeneron Pharmaceuticals

Paying an excellent price for high-flying biotech stocks and holding has been a profitable investing strategy.

2 Best Biotech Stocks to Buy in December

Gilead (GILD) company, Kite, gets conditional marketing authorization for CAR T cell therapy, Tecartus.

Gilead's (GILD) CAR T Cell Therapy Tecartus Wins EC Nod

Gilead (GILD) decides to not pursue FDA approval of filgotinib for the treatment of RA.

Gilead (GILD) to Not Seek FDA Approval of RA Drug, Amends Deal

Galapagos N.V. (NASDAQ: GLPG) was crushed on Wednesday after the firm, in conjunction with Gilead Sciences Inc.

Why Gilead Retreated on Rheumatoid Arthritis Treatment

Galapagos

Gilead Sciences cut its losses on a rheumatoid arthritis treatment in partnership with Galapagos, sending GLPG stock tumbling on Wednesday. Gilead stock also fell less than 1%.

Galapagos Stock Crumbles After Its Gilead Arthritis Deal Falls Apart

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission has granted conditional marketing authorization for Tecartus™ (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19). Tecartus is a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor. Conditional authorizat

Kite's Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe

FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & Nasdaq: GLPG) today announced that the companies have agreed to amend their existing arrangement for the commercialization and development of Jyseleca (filgotinib). This announcement follows a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the points raised in the Complete Response Letter (CRL) related to the New Drug Application (NDA) for f

Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca® (Filgotinib)

-- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 --

Gilead  and  Galapagos  announce  New  Commercialization  and  Development  Agreement  for  Jyseleca®  (filgotinib)  

Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH recently announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash, payable upon closing of the transaction plus a potential future milestone payment of up to €300 million. The post Why Gilead Sciences (GILD) Is Buying MYR GmbH For Up To €1.45 Billion appeared first on Pulse 2.0.

Why Gilead Sciences (GILD) Is Buying MYR GmbH For Up To €1.45 Billion

Gilead Sciences has continued its massive acquisition spree with a recent acquisition of more than $1 billion. The company has a long-term ability to continue paying dividends (at nearly 5%) and an exciting new asset portfolio from dividends.

Gilead Sciences Continues Its Massive Acquisition Spree, Don't Miss Out

Gilead (GILD) will purchase MYR GmbH for EUR1.15 billion and add HDV treatment Hepcludex to its portfolio.

Gilead (GILD) to Buy MYR GmbH for EUR1.15 Billion in Cash

Horizon Pharma

Horizon Therapeutics PLC (NASDAQ:HZNP) and Gilead Sciences Inc (NASDAQ:GILD) are two contrasting stocks from the drug manufacturing industry, in my opinion. What they share is a price that has pulled back recent highs, but that doesn't necessarily make both of them bargains.

Horizon Therapeutics vs. Gilead

GILD recently acquired MYR GmbH and its HDV drug for $1.4 billion. HDV is a liver disease that infects those with HBV. GILD's Vemlidy treats HBV and its revenue is growing at double-digits. The HDV deal looks enticing from a strategic standpoint.

Gilead's New Hepatitis Deal Is Enticing

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) is presenting new data from the Phase 3 ASCENT trial of Trodelvy® (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer (mTNBC) at the 2020 San Antonio Breast Cancer Symposium being held virtually December 8-11, 2020. The new data and analyses from the ASCENT trial continue to demonstrate the high clinical activity of Trodelvy in this patient population with traditionally poor outcomes. Trodelvy is a T

Gilead Advances Oncology Portfolio With New Data From Phase 3 ASCENT Trial of Trodelvy® in Metastatic Triple Negative Breast Cancer

Aytu BioScience

The day dawned as an M&A Thursday for the biotech sector, as a slew of deals of varied sizes were announced, with Gilead Sciences, Inc. (NASDAQ: GILD) and Aytu BioScience, Inc. (NASDAQ: AYTU) in the mix. Gilead Snaps Up Germany Drug Company In $1B Deal: Large-cap pharma Gilead announced Thursday an agreement to acquire German biotech MYR, which focuses on therapeutics for chronic hepatitis delta virus, or HDV, for an upfront payment of 1.15 billion euros ($1.39 billion) in cash, payable upon closing of the transaction, and 300 million euros ($363 million) in potential future milestone payments.

Merger Thursday: Gilead Buys German Drug Company, Aytu-Neos All-Stock Deal, Boehringer Picks Up NBE-Therapeutics

The biotech giant from California will acquire German drug developer MYR for around $1.4 billion.

Gilead Sciences Buys a New Hepatitis Delta Virus Treatment

Alexion Pharma

Amgen

Moderna

Vertex Pharmaceuticals

The short interest data is out for November 30, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

News for Gilead Sciences Stock (GILD)